Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1996 1
1998 1
1999 2
2003 1
2006 1
2009 2
2010 1
2011 1
2012 1
2016 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Cardiac arrest caused by trigeminal neuralgia.
Gottesman MH, Ibrahim B, Elfenbein AS, Mechanic A, Hertz S. Gottesman MH, et al. Headache. 1996 Jun;36(6):392-4. doi: 10.1046/j.1526-4610.1996.3606392.x. Headache. 1996. PMID: 8707560
Spinal subdural empyema: appearance on intraoperative sonography.
Price DB, Gottesman MH, Adelman R, Schneider SJ. Price DB, et al. Among authors: gottesman mh. J Ultrasound Med. 1993 Aug;12(8):493-5. doi: 10.7863/jum.1993.12.8.493. J Ultrasound Med. 1993. PMID: 8105104 No abstract available.
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.
Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J; New York State Multiple Sclerosis Consortium. Weinstock-Guttman B, et al. Among authors: gottesman mh. Mult Scler. 2003 Jun;9(3):293-8. doi: 10.1191/1352458503ms909oa. Mult Scler. 2003. PMID: 12814178
A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.
Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH. Jacobs LD, et al. Among authors: gottesman mh. Mult Scler. 1999 Oct;5(5):369-76. doi: 10.1177/135245859900500511. Mult Scler. 1999. PMID: 10516782
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
14 results